menu
    • menu
    [{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-770767","moa":"11-beta-HSD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CSL_112","moa":"ABCA1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IKT-001PRO","moa":"ABL\/PDGFR?\/PDGFR?\/c-Kit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABLi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KER-012","moa":"ACVR2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APD418","moa":"Adrenergic receptor beta-3 (ADRB3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"ISIS 703802","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION904","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"CiVi007","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"CiVi007","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS apoC-III Rx","moa":"ApoC-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"ISIS 678354","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PL-3994","moa":"Atrial natriuretic peptide receptor A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Ixmyelocel-T","moa":"Autologous bone marrow cells","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vericel Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vericel Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Medtronic plc","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Medtronic plc"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Erenumab","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CXL-1020","moa":"Calcium sensitizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CXL-1020","moa":"Calcium sensitizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986435","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CK-4021586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MYK-224","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2484595","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2484595","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Mayo Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"JNJ-39588146","moa":"CRHR2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS CRP Rx","moa":"CRP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Morgan Stanley"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions"},{"orgOrder":0,"company":"Columbia University","sponsor":"MedImmune | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"MEDI6012","moa":"enzymes; steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ MedImmune | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ MedImmune | AstraZeneca"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BIIB131","moa":"EPHX2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MAA868","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Covance"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ University of California, Los Angeles"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rostafuroxin","moa":"fluoroquinolone derivatives","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS-FXIRx","moa":"FXI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ponsegromab","moa":"monoclonal antibodies: mouse","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Amiodarone Hydrochloride","moa":"HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Cleveland Clinic \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ AstraZeneca"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Pegylated Carboxyhemoglobin Bovine","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanifit","sponsor":"Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SNF472","moa":"Hydroxyapatite (HA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanifit \/ Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Sanifit \/ Clinipace Worldwide"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silver Creek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Undisclosed"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silver Creek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Pacibekitug","moa":"IL6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tourmaline Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ubenimex","moa":"immunostimulants","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ubenimex","moa":"immunostimulants","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CeleCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"St. Antonius Hospital | Diagram","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Precision For Medicine | CirQuest Labs | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CeleCor Therapeutics \/ Precision For Medicine | CirQuest Labs | Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Precision For Medicine | CirQuest Labs | Syneos Health"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"KPL-914","moa":"Interleukin-1 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MLDL1278A","moa":"LILRB4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ BioInvent","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ BioInvent"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"Apolipoprotein(a) (LPA)||LPA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"LPA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"CervoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAP kinase p38 alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LY2623091","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Selonsertib","moa":"Mitogen-activated protein kinase kinase kinase 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CXL-1427","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CXL-1427","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LMI 1195","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Complexa","sponsor":"Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complexa \/ Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute"},{"orgOrder":0,"company":"Complexa","sponsor":"Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complexa \/ Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CervoMed","sponsor":"University of California, Los Angeles | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CervoMed \/ University of California, Los Angeles | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ University of California, Los Angeles | University of Virginia"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MPSK3169A","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-54452840","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PF-00489791","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PF-03049423","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Imara","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Imara","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Imara"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"},{"orgOrder":0,"company":"Thrombolytic Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Mutant Pro-Urokinase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thrombolytic Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thrombolytic Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Thrombolytic Science \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MST-188","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vepoloxamer","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Liquidia Corporation \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Liquidia Corporation \/ FGK Clinical Research"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ United Therapeutics"},{"orgOrder":0,"company":"Ischemix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CMX-2043","moa":"Proto-oncogene c-Met (MET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ischemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ischemix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ischemix \/ Undisclosed"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tetherex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SelK2","moa":"P-selectin glycoprotein ligand 1 (SELPLG)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tetherex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetherex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetherex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"JTT-251","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JTT-861","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akros Pharma \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Icon Plc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LY3540378","moa":"RXFP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BMS-986259","moa":"RXFP1\/RXFP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Sequel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K201","moa":"Ryanodine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sequel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sequel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K201","moa":"Ryanodine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sequel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARM210","moa":"RYR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARMGO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Chang Gung University","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Chang Gung University","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Chang Gung University"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Momentum Research Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Windtree Therapeutics \/ Momentum Research Inc","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Momentum Research Inc"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"University Medicine G\u00f6ttingen, Cardiac Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ University Medicine G\u00f6ttingen, Cardiac Center","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ University Medicine G\u00f6ttingen, Cardiac Center"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"scPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ scPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ scPharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sanofi | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ataciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Sanofi | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Sanofi | National Institutes of Health"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Praliciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Cyclerion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Akebia Therapeutics \/ Cyclerion Therapeutics"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CAT-2003","moa":"SREBP-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CAT-2003","moa":"SREBP-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAT-2054","moa":"SREBP-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAT-2054","moa":"SREBP-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kardigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Tonlamarsen","moa":"STAT3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kardigan \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Halozyme Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"LY3015014","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"LY3015014","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedy Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"University of Maryland | Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedy Pharmaceuticals \/ University of Maryland | Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ University of Maryland | Massachusetts General Hospital"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"AGN-151607","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"JNJ-64179375","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"VK2809","moa":"Thyroid hormone receptor beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Genentech"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Altavant Sciences \/ Altavant Sciences | PPD","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Altavant Sciences | PPD"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Takeda Pharmaceutical | Detiger Funds","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayo Clinic \/ Takeda Pharmaceutical | Detiger Funds","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Takeda Pharmaceutical | Detiger Funds"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olmesartan Medoxomil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Undisclosed"},{"orgOrder":0,"company":"Genervon Biopharmaceuticals","sponsor":"University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GM602","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genervon Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genervon Biopharmaceuticals \/ University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui","highestDevelopmentStatusID":"8","companyTruncated":"Genervon Biopharmaceuticals \/ University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Thymosin Beta-4","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AB-1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AB-1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Optigenex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AC-11","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Optigenex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Optigenex, Inc"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"CardioCell","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemedica Cell Technologies \/ CardioCell","highestDevelopmentStatusID":"8","companyTruncated":"Stemedica Cell Technologies \/ CardioCell"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Longview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Longview Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Longview Ventures"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BMS-914392","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Adventa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Breastmilk","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Adventa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Adventa Biosciences"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRD-4730","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CSL112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CSL112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Bota Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Ecklonia Cava Phlorotannin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bota Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bota Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bota Bio \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Enclitide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"StemCyte","sponsor":"StemCyte","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Blood Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCyte \/ StemCyte","highestDevelopmentStatusID":"8","companyTruncated":"StemCyte \/ StemCyte"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ISIS 757456","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"ISIS 757456","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Mayo Clinic | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-Star Biotech \/ Mayo Clinic | PPD","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Mayo Clinic | PPD"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ TIMI Study Group"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ BTIG"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NBS10","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NKPL66","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Grace Therapeutics \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Grace Therapeutics \/ JSS Medical Research"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OPL-0301","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amnio Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amnio Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"L-Nutra | Peak Human Labs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Peak Human Labs Calorie Mimetic Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ L-Nutra | Peak Human Labs","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ L-Nutra | Peak Human Labs"},{"orgOrder":0,"company":"Celularity","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Placenta Derived Cell PDA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Celgene Corporation"},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia \/ CellProthera"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"ACCESS Community Health Network | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Quartet","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN7544","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Reven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Icon Plc | ERT: Clinical Trial Technology Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reven Pharmaceuticals \/ Icon Plc | ERT: Clinical Trial Technology Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Icon Plc | ERT: Clinical Trial Technology Solutions"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARM210","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMGO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"SRW","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"SRW Cel System","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TruDiagnostic \/ SRW","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ SRW"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"E-Star Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Undisclosed"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"E-Star Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vasomera","moa":"Helodermin-preferring VIP receptor (VIPR2)||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivacelle Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Vivacelle Bio \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ US Navy"},{"orgOrder":0,"company":"Humacyte","sponsor":"Atlantic Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Atlantic Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Atlantic Research Group"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Texas Health Resources | Michigan State University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Texas Health Resources | Michigan State University","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Texas Health Resources | Michigan State University"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Aires Pharmaceuticals | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mayo Clinic \/ Aires Pharmaceuticals | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Aires Pharmaceuticals | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"TheraVasc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TheraVasc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TheraVasc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TheraVasc \/ Undisclosed"},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ JanOne"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Alliance Global Partners"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ SPYR Technologies"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XC001","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XC001","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Longeveron","sponsor":"National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Lomecel-B","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG0001","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"||Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aisa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BMS-919373","moa":"Voltage-gated potassium channel Kv1.5 (KCNA5)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BMS-919373","moa":"Voltage-gated potassium channel Kv1.5 (KCNA5)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Undisclosed"},{"orgOrder":0,"company":"Allrock Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"ROC-101","moa":"ROCK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Allrock Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Allrock Bio \/ Versant Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allrock Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"REGN7508","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Vardenafil Hydrochloride","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Respira Therapeutics \/ Gossamer Bio","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Gossamer Bio"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"American Heart Association | University of Michigan | Oakland University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"KER-012","moa":"ACVR2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ American Heart Association | University of Michigan | Oakland University","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ American Heart Association | University of Michigan | Oakland University"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Palak Shah","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Palak Shah","highestDevelopmentStatusID":"8","companyTruncated":"Abbott Laboratories \/ Palak Shah"},{"orgOrder":0,"company":"Complexa","sponsor":"Mark Gladwin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complexa \/ Mark Gladwin","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Mark Gladwin"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Jakob Stensballe","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellphire Therapeutics \/ Jakob Stensballe","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Jakob Stensballe"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ken Mahaffey","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vorapaxar Sulfate","moa":"Proteinase-activated receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Ken Mahaffey","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Ken Mahaffey"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Harvey Hahn","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Harvey Hahn","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Harvey Hahn"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Jeffrey Rade","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Jeffrey Rade","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Jeffrey Rade"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bastiaan Driehuys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hyperpolarized Xenon-129","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Bastiaan Driehuys","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Bastiaan Driehuys"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Pacibekitug","moa":"IL-6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin...

                            Details : In a post hoc analysis of CABG patients aged 65 years and older treated with 125 units of AGN-151607, a botulinum toxin type A, is a novel investigational neurotoxin the study found a greater risk reduction at 51 percent compared to placebo (nominal p<0....

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Pa...

                            Details : Elezanumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 16, 2020

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGN-151607

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Particip...

                            Details : AGN-151607 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 19, 2018

                            Lead Product(s) : AGN-151607

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treat...

                            Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endocarditis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 11, 2017

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Respira Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Respira Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vardenafil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Gossamer Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Respira Therapeutics Grants Gossamer Option to Acquire It from Samsara BioCapital

                            Details : Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH).

                            Product Name : RT234

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : Vardenafil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Gossamer Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allrock Bio

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Allrock Bio

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ROC-101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Versant Ventures

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            AllRock Bio Raises $50 million to Drive Therapy for Pulmonary Hypertension into Phase 2

                            Details : The proceeds will advance AllRock's lead molecule, ROC-101, a first-in-class, oral ROCK inhibitor, which the company exclusively licensed from Sanofi, into Phase 2 clinical development.

                            Product Name : ROC-101

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 16, 2025

                            Lead Product(s) : ROC-101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Versant Ventures

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Retension Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Retension Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RTN-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Modified Release RTN-001 In Patients with Uncontrolled Hypertension

                            Details : RTN-001 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : RTN-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Marea Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Marea Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAR001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : TIMI Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of MAR001 in Adults with Elevated Triglycerides and Remnant Cholesterol

                            Details : MAR001 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hypertriglyceridemia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 19, 2025

                            Lead Product(s) : MAR001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : TIMI Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CervoMed

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            CervoMed

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Oral Neflamapimod Effect on Motor Recovery After Acute Ischaemic Stroke

                            Details : Neflamapimod is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2025

                            Lead Product(s) : Neflamapimod

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cytokinetics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CK-4021586

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results...

                            Details : CK-4021586 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure, Diastolic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2025

                            Lead Product(s) : CK-4021586

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth